GO
Loading...

Enter multiple symbols separated by commas

Search results for "ASPX"

REFINE RESULTS

SEARCH RESULTS

About 6 results. Sort By: Date | Relevance
Rich Synageva M&A premium epitomizes appetite for orphan drugs

May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...
Source: Reuters | By: Olivia Oran
UPDATE 4-Alexion to bolster rare disease offering with $8.4 bln deal

*Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...
Source: Reuters | By: Vidya L Nathan, Natalie Grover and Bill Berkrot
UPDATE 3-Alexion bolsters rare disease drugs business with $8.4 bln deal

*Alexion offers $225.92 per Synageva share in cash and stock. May 6- Drugmaker Alexion Pharmaceuticals Inc agreed to buy Synageva BioPharma Corp for $8.4 billion at a hefty premium to expand in the lucrative market for drugs that treat rare diseases. The drug, whose marketing application is being reviewed in the United States and Europe, treats a rare and...
Source: Reuters | By: Vidya L Nathan and Natalie Grover
Two pharma giants merge in $8.4B deal

Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.
Source: Reuters
UPDATE 1-Alexion Pharma to buy Synageva BioPharma for $8.4 bln

May 6- Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to boost its rare drug pipeline. Kanuma's marketing application is being reviewed in the United States and Europe. Recent deals involving rare disease companies include Teva Pharmaceutical Industries Inc's $3.5 billion purchase of Auspex...
Source: Reuters
EXCLUSIVE-Pfizer is mystery bidder for rare disease drugmaker Sobi -sources

NEW YORK/ LONDON, April 30- Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB, the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said. Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach, but Biogen and...
Source: Reuters | By: Olivia Oran, Ben Hirschler and Pamela Barbaglia